SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : GMED - GenoMed Inc.
GMED 82.16-2.1%10:37 AM EST

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: jmhollen who started this subject10/31/2002 11:28:12 AM
From: jmhollen   of 347
 
Med Hires Chief Scientific Officer from Johns Hopkins

ST. LOUIS, Oct. 31 /PRNewswire-FirstCall/ -- GenoMed, Inc. (OTC Pink Sheets: GMED) ("the Company" or "GenoMed"), a St. Louis, Missouri-based medical genomics biotechnology company, announced today that Paula Hempen, Ph.D. has joined the Company as its Chief Scientific Officer.


Dr. Hempen has extensive research experience in cancer genetics, the regulation of gene transcription, immunology, and genomics. Dr. Hempen spent the last three years in the laboratory of Dr. Scott Kern at the Sydney Kimmel Comprehensive Cancer Center at Johns Hopkins University in Baltimore, Maryland. Dr. Hempen's research at Hopkins led to the discovery of two new tumor suppressor genes in pancreatic cancer. Her findings have recently been submitted for publication.

Dr. David Moskowitz, GenoMed's Chairman, said, "With her cutting-edge experience in molecular biology, bioinformatics, molecular genetics, immunology and especially cancer genetics, Dr. Hempen is a wonderful addition to the GenoMed team." Dr. Hempen said, "I am very excited to be a part of the GenoMed team and to begin the adventure of discovery here in my hometown of St. Louis."

Dr. Moskowitz concluded, "I am thrilled that a scientist of Dr. Hempen's excellence has joined us, and I am delighted to entrust our scientific endeavor to her capable hands."

About GenoMed

GenoMed, Inc. is a medical genomics company whose mission is to improve patient outcomes by identifying the genes that cause disease. Two recent publications detail the Company's unique treatment approach, and the large number of age-related diseases that it may be applicable to. Having developed a novel treatment for cardiovascular disease, the Company is now working on an early-warning system for cancer, starting with colon cancer.

For questions, please contact Krissy Fischer, tel. 1-877-GENOMED (1-877-436-6633), FAX 314-977-0042, email: kfischer@genomedics.com, or visit GenoMed at www.genomedics.com.

SOURCE GenoMed, Inc.

CONTACT: Krissy Fischer of GenoMed, Inc., +1-877-436-6633, or fax,
+1-314-977-0042, or kfischer@genomedics.com

Web site: genomedics.com

.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext